View Older Stories View More Recent Stories

Jun 7, 2024 03:24PM ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
May 27, 2024 11:33AM NATIONALLY RANKED ROSEN LAW FIRM Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
May 15, 2024 03:30PM ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
May 8, 2024 07:00AM Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
May 1, 2024 03:01PM AKRO INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
Apr 30, 2024 08:00AM Akero Therapeutics (AKRO) Appoints Scott Gangloff as Chief Technology Officer
Apr 30, 2024 08:00AM Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
Mar 7, 2024 04:01PM Akero Therapeutics (AKRO) Reports Publication of Phase 2b SYMMETRY Cohort D Study
Mar 7, 2024 04:01PM Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
Mar 4, 2024 06:02AM Akero Therapeutics (AKRO) Posts Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
Mar 4, 2024 06:00AM Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
Feb 29, 2024 08:00AM Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
Feb 29, 2024 07:00AM Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Jan 3, 2024 08:15AM Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Jan 3, 2024 08:15AM Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 18, 2023 07:00AM Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
Nov 13, 2023 07:00AM Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Nov 10, 2023 08:57AM Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
Nov 8, 2023 07:00AM Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
Oct 17, 2023 04:05PM Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
Oct 10, 2023 07:00AM Akero Therapeutics (AKRO) Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study
Oct 10, 2023 07:00AM Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of L
Oct 9, 2023 04:05PM Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
Oct 4, 2023 08:02AM Akero Therapeutics (AKRO) Announces Publication of the Harmony Phase 2b Trial Results
Oct 4, 2023 08:00AM Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
Oct 4, 2023 08:00AM Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
Aug 31, 2023 07:00AM Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
Aug 28, 2023 07:00AM Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
Aug 11, 2023 06:00AM Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Jun 23, 2023 07:00AM Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
Jun 23, 2023 07:00AM Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
Jun 5, 2023 07:00AM Akero Therapeutics (AKRO) Reports Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints
Jun 5, 2023 07:00AM Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
Jun 5, 2023 07:00AM Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Diseas
Jun 1, 2023 04:05PM Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
May 31, 2023 08:00AM Akero Therapeutics to Present at the Jefferies Healthcare Conference
May 15, 2023 07:00AM Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Mar 29, 2023 04:01PM Akero Therapeutics (AKRO) Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin
Mar 29, 2023 04:01PM Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
Mar 29, 2023 04:01PM Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
Mar 17, 2023 07:00AM Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Mar 17, 2023 07:00AM Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Jan 10, 2023 08:00AM Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
Jan 10, 2023 08:00AM Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
Jan 4, 2023 08:00AM Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Jan 4, 2023 08:00AM Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 21, 2022 04:01PM Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
Dec 21, 2022 04:01PM Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
Dec 8, 2022 07:02AM Akero Therapeutics (AKRO) Announces Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
Dec 8, 2022 07:00AM Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
View More Recent Stories View Older Stories